登录 | 注册    关注公众号  
微信公众号
搜索
 > 【TNFSF11】

TNFSF11信息

英文名称:Tumor necrosis factor ligand superfamily member 11
中文名称:肿瘤坏死因子配体超家族成员11
靶点别称:Osteoclast differentiation factor,TRANCE,TNFSF11,TNF-related activation-induced cytokine,Tumor necrosis factor ligand superfamily member 11,CD254,TNF Superfamily Member 11,Osteoprotegerin Ligand,Receptor Activator Of Nuclear Factor Kappa B Ligand,Tumor Necrosis Factor Superfamily Member 11,ODF,RANKL,OPGL,CD254 Antigen,HRANKL2,TNLG6B,OPTB2,SOdf,RANK Ligand,Tumor Necrosis Factor (Ligand) Superfamily, Member 11,Receptor Activator Of Nuclear Factor Kappa-B Ligand,Tumor Necrosis Factor Ligand 6B
上市药物数量:7
临床药物数量:27
最高研发阶段:批准上市

TNFSF11分子别名

RANKL,CD254,TRANCE,OPGL,ODF

TNFSF11分子背景

Receptor activator of nuclear factor kappa-B ligand (RANKL), also known as tumor necrosis factor ligand superfamily member 11 (TNFSF11), TNF-related activation-induced cytokine (TRANCE), osteoprotegerin ligand (OPGL), and osteoclast differentiation factor (ODF), is known as a type II membrane protein and is a member of the tumor necrosis factor (TNF) superfamily. RANKL, through its ability to stimulate osteoclast formation and activity, is a critical mediator of bone resorption and overall bone density. Some findings also suggestion some cancer cells, particularly prostate cancer cells, can activate an increase in bone remodeling and ultimately increase overall bone production.[17] This increase in bone remodeling and bone production increases the overall growth of bone metastasizes. The overall control of bone remodeling is regulated by the binding of RANKL with its receptor or its decoy receptor, respectively, RANK and OPG.

TNFSF11上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验

TNFSF11临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验

消息提示

请输入您的联系方式,再点击提交!

确定